Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
2024; American Medical Association; Linguagem: Inglês
10.1001/jamadermatol.2024.4688
ISSN2168-6084
AutoresApril W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim Papp, Renata M. Kisa, John Vaile, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Julie Scotto, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt,
Tópico(s)Pharmaceutical studies and practices
ResumoSafe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Referência(s)